Hemostatics are substances or devices designed to stop bleeding, whether by speeding up the body’s own clotting process, physically sealing a wound, or both. They range from simple gauze impregnated with clotting minerals to injectable drugs and experimental nanoparticles that mimic the behavior of platelets. The field spans everyday first aid, battlefield medicine, and high-stakes surgical care, and the technology has changed considerably in just the past two decades, driven largely by lessons from combat trauma.
How the Body Stops Bleeding on Its Own
To understand what hemostatic agents actually do, it helps to know what they are assisting. When a blood vessel is damaged, the body launches a multi-step response. Platelets rush to the injury site, stick to exposed collagen in the vessel wall, and clump together to form a temporary plug. Simultaneously, a cascade of proteins in the blood activates one another in sequence until the enzyme thrombin appears. Thrombin converts a soluble blood protein called fibrinogen into fibrin, which assembles into tough, interlocking fibers that reinforce the platelet plug into a stable clot.1PubMed Central. Fibrinogen and fibrin: An illustrated review Nearly every hemostatic product on the market targets one or more steps in this sequence: some activate the clotting cascade faster, some provide a scaffold for clot formation, some prevent the body from breaking clots down too soon, and some attempt to do all three.
Topical Hemostats Used in Surgery
Surgeons have relied on absorbable topical hemostats for decades. These are materials placed directly onto a bleeding surface inside the body and left in place, where they gradually dissolve over days or weeks. The most common categories include gelatin sponges, oxidized cellulose sheets, and microfibrillar collagen pads. Gelatin products swell when they contact blood, filling the wound space and giving platelets a surface to cling to. Oxidized cellulose has a low pH that promotes clot formation on contact. Collagen-based hemostats attract and activate platelets directly, since collagen is the natural trigger platelets respond to in a damaged vessel wall.
Chitosan, derived from the shells of crustaceans, works through a different mechanism. It carries a positive electrical charge, while red blood cells carry a negative one. Research using optical tweezers has measured the direct adhesion force between a red blood cell and chitosan at only a few piconewtons, far too weak on its own to explain the rapid clotting effect clinicians observe.2Journal of Mechanics. Mechanics for the Adhesion and Aggregation of Red Blood Cells on Chitosan The real mechanism appears to be chemical: chitosan releases hydrogen ions into the surrounding blood, and those ions neutralize the repulsive charge between neighboring red blood cells. Once the cells stop repelling each other, they pack tightly against the chitosan surface and form a dense barrier that plugs the wound. This understanding has made chitosan the basis for several combat dressings discussed below.
Mineral and Inorganic Agents
Kaolin, a natural clay mineral, accelerates clotting by jumpstarting a part of the coagulation cascade known as the contact pathway. In microfluidic experiments mimicking blood flow at venous speeds, adding kaolin to a surface shortened the time to fibrin formation by roughly 100 seconds compared to collagen alone.3PubMed Central. Contact activation of blood coagulation on a defined kaolin/collagen surface in a microfluidic assay That acceleration matters in a wound where every second of continued bleeding means more blood loss. Kaolin is now the active ingredient in QuikClot Combat Gauze, the hemostatic dressing currently issued to U.S. military personnel.
Zeolite granules, the original QuikClot formulation, were the first widely used mineral hemostat in combat. They worked by absorbing water from blood at the wound site, concentrating clotting factors in a smaller volume. The problem was heat. Absorbing water triggered a vigorous exothermic reaction, and early versions could produce dangerously high temperatures at the wound surface. A case series from combat operations documented cutaneous burns caused by zeolite use during treatment of major hemorrhage.4PubMed. A case series describing thermal injury resulting from zeolite use for hemorrhage control in combat operations Later reformulations (marketed as ACS+) reduced the peak temperature at the dressing-tissue interface to around 40°C, compared to roughly 61°C for the original version, a meaningful improvement but still warmer than body temperature.5PubMed. Exothermic reaction in zeolite hemostatic dressings: QuikClot ACS and ACS+ The burn risk was a major reason the military eventually shifted to kaolin-based gauze instead of granular zeolite.
Combat Gauze and Prehospital Dressings
Battlefield hemorrhage control has driven more innovation in hemostatics than almost any other setting, because uncontrolled bleeding from extremity wounds is one of the leading preventable causes of death in combat. Two dressing families now dominate: kaolin-impregnated gauze (QuikClot Combat Gauze, or QCG) and chitosan-based dressings (Celox Gauze, ChitoGauze, and Celox Rapid).
Head-to-head animal studies have generally favored kaolin gauze. In one controlled comparison, QCG achieved initial hemostasis in all subjects, while Celox Rapid managed it in 70 percent. Over a one-hour observation window, every QCG-treated animal maintained hemostasis with zero additional bleeding, whereas 40 percent of the Celox Rapid group continued to bleed, with a mean blood loss of about 162 mL in the failures. The researchers calculated that QCG had roughly 16 times greater odds of success over the hour-long period.6American Journal of Disaster Medicine. The effects of QuikClot Combat Gauze and Celox Rapid on hemorrhage control That said, a broader review of third-generation dressings found that chitosan-based products like Celox Gauze and ChitoGauze performed comparably to Combat Gauze across many outcome measures.7Military Medicine. Review of New Topical Hemostatic Dressings for Combat Casualty Care The practical takeaway for first responders and military medics is that both families are far better than plain gauze, with kaolin gauze having a slight edge in the most rigorous comparisons.
Systemic Drugs That Control Bleeding
Not all hemostatics are applied to wounds. Some are given intravenously to treat bleeding from the inside. Tranexamic acid (TXA) is the most widely used systemic hemostatic drug. It works by blocking the enzymes that break down fibrin, the structural protein that holds a clot together.8PubMed. Tranexamic acid in trauma: how should we use it? By slowing this breakdown, TXA gives clots more time to do their job. It is used in trauma care, surgery, and heavy menstrual bleeding, and is on the World Health Organization’s list of essential medicines.
Recombinant activated factor VII (rFVIIa) is a more potent and more controversial option. It is a lab-made version of a clotting factor and was originally developed for hemophilia patients. It has been tried as a last-resort treatment in severe trauma. In a pair of randomized, placebo-controlled trials, rFVIIa reduced red blood cell transfusion requirements in blunt trauma patients by an estimated 2.6 units and cut the rate of massive transfusion from about a third of patients to 14 percent.9Journal of Trauma and Acute Care Surgery. Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-Blind Clinical Trials But the drug has clear limits. In a study of coagulopathic trauma patients who were severely acidotic, with blood pH at or below 7.02 and high rates of ongoing bleeding, every single patient who received rFVIIa died.10PubMed Central. The utility of recombinant factor VIIa as a last resort in trauma The clotting cascade depends on enzymes that function poorly in acidic conditions, so flooding the system with one more clotting factor cannot overcome the underlying metabolic disaster.
Why Hypothermia and Acidosis Make Bleeding Worse
The failure of rFVIIa in severely acidotic patients points to a broader problem in trauma: the body’s clotting system degrades rapidly when a patient is cold, acidotic, or both. These two conditions are extremely common in major hemorrhage, because blood loss leads to poor tissue perfusion, which produces lactic acid, and the resulting shock drops body temperature. Research on human whole blood has shown that hypothermia and acidosis do not just add together but synergistically impair clotting, worsening clot formation times and reducing clot firmness far more than either condition alone.11PubMed. Hypothermia and acidosis synergistically impair coagulation in human whole blood
The two conditions also attack the clotting system through different vulnerable points. Hypothermia mainly slows the initiation of thrombin production and inhibits the liver’s ability to make new fibrinogen. Acidosis, by contrast, impairs the propagation phase of thrombin generation and accelerates fibrinogen degradation, depleting the very building material clots are made of.12PubMed. Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability This is why trauma resuscitation protocols now prioritize warming the patient and correcting acidosis alongside transfusing blood products. No hemostatic agent, topical or systemic, can fully compensate for a clotting system that has lost both its speed and its raw materials.
Safety Concerns With Surgical Hemostats
Topical hemostats are generally safe when used correctly, but “used correctly” is doing a lot of work in that sentence. The materials are designed to be left inside the body temporarily, and problems arise when they swell more than expected, are placed in confined anatomical spaces, or are not fully removed at the end of surgery.
A ten-year analysis of adverse-event reports for gelatin-thrombin hemostats used in neurosurgery found that the two major product types caused different patterns of complications. The granular bovine-derived product (Floseal) was associated with a higher proportion of compressive neurological deficits, consistent with the material expanding in tight spaces around the brain and spinal cord. The flowable porcine-derived product (Surgiflo) was associated with more reports of postoperative infection and mass-effect accumulation, likely because it spreads more widely along surgical planes and leaves a larger surface area of retained material.13PubMed. Post-market surveillance of gelatin-thrombin hemostats in neurosurgery: a 10-year MAUDE Analysis The researchers emphasized the importance of thorough removal and washout of hemostatic matrix from confined neural corridors before closing.
Microfibrillar collagen hemostats have caused similar trouble. In one documented case, retained collagen hemostat after spinal surgery formed a granulomatous mass that compressed a nerve root, producing symptoms that mimicked recurrence of a disc herniation. A second surgery was required to remove the mass, which turned out to be composed mainly of the hemostat material itself.14PubMed. Radiculopathy due to microfibrillar collagen hemostat mimicking recurrence of disc herniation These complications are uncommon but serve as a reminder that hemostatic agents are not inert fillers. They interact with tissue, can trigger inflammatory responses, and need to be treated with the same care as any implanted material.
Bleeding on Blood Thinners
One of the trickiest clinical scenarios for hemostasis involves patients who are already on anticoagulant medications. Millions of people take warfarin, heparin, or newer direct oral anticoagulants to prevent strokes and blood clots, and when those patients have a traumatic injury or need emergency surgery, their chemically suppressed clotting system makes bleeding harder to stop. Reversal strategies exist for each drug class, but they are constantly evolving as new anticoagulants enter the market.15PubMed Central. Emergency Reversal of Anticoagulation Vitamin K reverses warfarin over hours, protamine sulfate neutralizes heparin within minutes, and specific antidotes like idarucizumab can reverse dabigatran almost immediately. For the newer factor Xa inhibitors, andexanet alfa is available but expensive and not universally stocked.
From the hemostatics side, researchers have also been designing wound dressings that work even when the patient’s blood is pharmacologically thinned. One experimental approach used a carefully engineered porous structure to physically trap blood cells and promote clotting through mechanical means rather than relying on the coagulation cascade. In animal models, this material stopped bleeding from liver wounds, carotid artery injuries, and even human radial artery puncture sites within minutes, with significantly reduced blood loss, even in animals receiving anticoagulant therapy.16PubMed Central. An architecturally rational hemostat for rapid stopping of massive bleeding on anticoagulation therapy This line of research matters because the population taking blood thinners is large and growing, and current hemostatic products were largely developed and tested on subjects with normal clotting ability.
Next-Generation Hydrogel Hemostats
Beyond gauze and sponges, a new class of hemostatic materials is emerging: injectable or spreadable hydrogels that conform to irregular wound shapes, adhere to wet tissue, and deliver hemostatic activity at the molecular level. Many of these draw inspiration from mussels, the shellfish whose adhesive proteins let them cling to wet rocks in pounding surf. A mussel-inspired hemostatic hydrogel built from a gelatin and oxidized dextran network, enhanced with dopamine, reduced bleeding by 76 percent in a mouse liver hemorrhage model while remaining injectable, biocompatible, and biodegradable.17PubMed. Mussel-Inspired Hemostatic Hydrogel Adhesive Formulated from a Gelatin-Oxidized Dextrin Double Network
Another hydrogel combined chitosan with silk fibroin, cross-linked using tannic acid, and achieved roughly 96.5 percent hemostatic efficiency in animal models of arterial and visceral bleeding. Its adhesive strength on wet tissue was strong enough to physically seal wounds rather than just accelerating clot formation on their surface.18Bioactive Materials. A mussel-inspired supramolecular hydrogel with robust tissue anchor for rapid hemostasis of arterial and visceral bleedings Self-assembling peptide hydrogels represent yet another approach: short peptide chains that dissolve in water and spontaneously form nanoscale fiber networks. In rat models of vein and liver bleeding, one such peptide hydrogel achieved hemostasis about 38 seconds faster than a commercial hemostatic powder.19ACS Omega. Experimental Study on Rapid Hemostasis Using Peptide Hydrogels These hydrogels are still in preclinical testing, but their ability to be injected into deep or irregularly shaped wounds gives them a potential advantage over flat gauze or rigid sponges.
Synthetic Platelets and Self-Propelled Particles
Some of the most ambitious hemostatic research aims to create artificial versions of platelets themselves. One early proof-of-concept used polymer nanoparticles coated with a peptide sequence (RGD) that binds to activated natural platelets. When injected intravenously in animals with femoral artery injuries, these synthetic platelets accumulated at the wound site at more than double the rate of uncoated particles, suggesting they were actively homing to the injury rather than just getting passively swept into clots.20PubMed Central. Synthetic Platelets: Nanotechnology to Halt Bleeding More recent designs use liposomes decorated with multiple peptides that mimic different platelet functions: adhesion to the damaged vessel wall via von Willebrand factor and collagen, and aggregation through fibrinogen bridging between particles.21PubMed Central. Platelet-inspired synthetic nanoparticles improve hemostasis and hemodynamics in a rabbit model of abdominal hemorrhage
Perhaps the most unconventional approach involves self-propelled microparticles that physically swim upstream into a bleeding wound. These carbonate-based particles generate gas bubbles that push them through fluid at speeds up to 1.5 centimeters per second, carrying a cargo of thrombin several millimeters deep into the wound vasculature. In animal models of both surgical and traumatic bleeding, the thrombin-loaded self-propelled particles halted severe hemorrhage that conventional topical hemostats could not reach.22PubMed Central. Self-propelled particles that transport cargo through flowing blood and halt hemorrhage The concept addresses a real limitation of current hemostatics: most of them require direct contact with the bleeding surface, and in a deep or cavitary wound, that contact can be impossible to achieve. Particles that deliver clotting agents against the flow of blood could eventually change how non-compressible hemorrhage is treated, though the technology remains in early-stage animal testing and faces significant hurdles before clinical use, including demonstrating that gas-generating particles are safe inside human blood vessels.
What Civilians Should Know About Over-the-Counter Options
Most of the products discussed above are designed for surgical suites or military medics, but hemostatic technology has filtered into consumer first-aid kits as well. Kaolin-impregnated gauze is available to civilians under brand names like QuikClot and is increasingly carried by hikers, hunters, and people who work with power tools. Chitosan-based dressings are also sold commercially. For most household injuries, simple direct pressure with clean gauze is sufficient and remains the first-line recommendation from emergency medicine guidelines. Hemostatic dressings add the most value when bleeding is severe enough that direct pressure alone is not controlling it, when the wound is in a location where a tourniquet cannot be applied (like the trunk or neck), or when you are far from professional medical care.
If you carry hemostatic gauze, technique matters as much as the product itself. The gauze needs to be packed directly into the wound, not just laid on top, and then firm pressure must be held for at least three minutes. Pouring loose hemostatic granules into a wound, the approach used with old-style zeolite products, is no longer recommended because of the burn risk and the difficulty of ensuring contact with the actual bleeding source. Hemostatic agents are an addition to basic first-aid skills, not a replacement for them. Direct pressure, elevation, and tourniquets for extremity bleeding are still the foundation of civilian hemorrhage control.